-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A in adult patients with...
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene dezaparvovec has been given...
2023 CHS National Awards
Each year the CHS honours individuals who have made a significant contribution to improving the quality of life of people with bleeding disorders. The 2023 CHS National Awards will...
CHS Research programs – Time to apply!
The CHS is announcing its Call for Applications for its research programs for the 2023-2024 grant period. The deadline to submit applications for all the programs is December 16,...
INNOVATORS
BUILDER
Believers
